Breaks Categories: Stock Spotlights

FridayJun 10, 2022 12:44 pm

CannabisNewsBreaks – Flora Growth Corp.’s (NASDAQ: FLGC) Completion of Key Milestones Position It for Success

Flora Growth Corp. (NASDAQ: FLGC) recently announced financial and operating results for the 2021 fiscal year that show the success of its efforts as revenues and profits begin what is expected to be a rapid climb. “The year-end financial results show about $9 million in revenues, which is ‘significantly higher’ than those reported the prior year before the law change and Flora’s IPO launch on the Nasdaq Capital Market. The report maintains the company’s outlook for ending 2022 with revenues of $35 million to $45 million, which would be growth of between 288% and 400% over 2021. Much of Flora’s…

Continue Reading

FridayMay 27, 2022 2:57 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Leveraging DehydraTECH(TM) as It Looks to Tap into Various Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX) has been pushing the boundaries of drug delivery through its patented DehydraTECH(TM) technology, which has evidenced more efficient delivery of active pharmaceutical ingredients (“APIs”) into the bloodstream while also increasing their bioavailability. “Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the delivery of cannabinoids, nicotine, antivirals, PDE5 inhibitors, and more,” a recent article reads. “All of Lexaria’s efforts serve to demonstrate the superior performance of both its research program and its DehydraTECH drug delivery technology. By doing so,…

Continue Reading

FridayMay 13, 2022 1:54 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Devoting Research, Product Development to Make Drug Substances More Effective

Lexaria Bioscience Corp. (NASDAQ: LEXX) is devoting its research and product development to making drug substances more effective in the approach to treating medical conditions such as high blood pressure and, in the process, to overcoming many obstacles that may hinder their proper use by patients. “One area of Lexaria’s research has focused on pursuing U.S. Food and Drug Administration (‘FDA’) approval to begin formal, registered clinical testing of its DehydraTECH-processed cannabidiol (‘CBD’) for the treatment of hypertension under the Investigational New Drug (‘IND’) process,” a recent article reads. “Lexaria recently announced the launch of its HYPER-H21-4 randomized, double-blinded, placebo-controlled,…

Continue Reading

WednesdayMay 11, 2022 1:18 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Expanding Reach, Reports ‘Significant Balance Sheet and Operational Improvements’

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) has been strengthening its revenue streams in the states where it operates, particularly in Michigan, Florida and California of late, while also working to deal with its debt to make it more long-term feasible, announcing recently that it has eliminated several million dollars’ worth of liabilities and annual expenses. “The acquisition earlier this year of a 15,000-square-foot manufacturing, processing and distribution facility as well as properties owned by PharmaCo Inc., in Michigan, plus full licensing for manufacturing both medical and adult-use cannabis products in the state, assured RWB’s efforts to become fully…

Continue Reading

MondayMay 09, 2022 2:17 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging Advantage in Rare Cannabinoid Biosynthesis Space

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company currently developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high, unmet medical needs. The company’s focus is on rare cannabinoids, many of which are not yet available in commercial-size quantities, such as cannabidivarin – (“CBDV”) and tetrahydrocannabivarin – (“THCV”). “The acquisition of BayMedica in October 2021 has provided an advantage for InMed in the rare cannabinoid biosynthesis industry,” reads a recent article discussing the company. “BayMedica is a private U.S. firm specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector and…

Continue Reading

FridayMay 06, 2022 3:12 pm

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH-Nicotine Pouch Performance to Be Compared to That of Leading Brands

Lexaria Bioscience Corp. (NASDAQ: LEXX) is expected to begin dosing for the NIC-H22-1 human study this summer. “NIC-H22-1, a pharmacokinetic randomized, double-blinded, cross-over study involving 36 human participants, will compare Lexaria’s DehydraTECH-nicotine pouch performance to that of existing leading brands available to U.S. customers, namely ON! and Zyn,” a recent article reads. The human study NIC-H22-1 is expected to build on the successes of the company’s animal studies, which have proven the technology’s effectiveness in promoting faster absorption, higher peak absorption, and greater overall quantities of nicotine, on average, in the blood than concentration-matched control formulations. “In 2021, the company…

Continue Reading

FridayMay 06, 2022 1:20 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Expanding into Live Resin Vapes Segment to Capitalize on Growing Market

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF) recently announced the rollout of Platinum Vape(TM) (“PV”) Live Resin in Michigan, fulfilling its promise to introduce a steady stream of new products and consumption options to satisfy demand in the state. “The debut marks RWB’s line expansion into the higher-margin live resin vapes segment and also represents its inaugural product in Michigan beyond the popular distillate vape products. The company is committed to releasing many more products in the future,” a recent article reads. “Red White & Bloom expects PV Live Resin to become popular with consumers owing to the trust…

Continue Reading

ThursdayApr 28, 2022 3:05 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) is aware of the need to continuously improve its understanding of the capabilities and potential applications of its patented DehydraTECH(TM) drug delivery technology. This informs its long-held commitment to its applied research and development (“R&D”) programs. “So far, the company’s research journey has involved a series of controlled and well-designed in vitro preclinical testing and in vivo animal and human clinical studies…. Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research.…

Continue Reading

FridayApr 22, 2022 2:28 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Well Positioned for Opportunity

Flora Growth Corp. (NASDAQ: FLGC) has expanded its portfolio, which spans a range of verticals and diverse revenue streams, with growth largely driven through mergers and acquisitions (“M&As”). With M&As defining its 2021 calendar year, Flora Growth capitalized on global trends, which saw over 63,000 worldwide M&A transactions completed across all industries and sectors as companies sought new avenues for growth amid the pandemic, rising inflation and disrupted supply chains. With two recent acquisitions, Flora Growth “was able to add an estimated $35 million in revenues and $7 million EBITDA. For comparison, back in 2020, the company’s acquisitions generated $28…

Continue Reading

MondayApr 18, 2022 2:38 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Rare Cannabinoid Manufacturing Scale

InMed Pharmaceuticals (NASDAQ: INM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to the health and wellness market on a B2B basis,” a recent article reads. “The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates scales of cannabidivarin (‘CBDV’) and tetrahydrocannabivarin (‘THCV’) in the…

Continue Reading